Singulex is the developer and leading provider of single molecule counting (SMCTM) technology for clinical diagnostics and scientific discovery. Singulex's proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex's ultra-sensitive immunoassay solutions and lab testing services are designed to transform patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics. The firm provides immunoassay systems which includes benchtop analytical instrumentation, integrated and prepared reagents for ultrasensitive immunoassays, and software to automatically analyze data and display detailed assay reports. Also offered is SgxHD for cardiovascular monitoring, and custom services and support, such as sample testing, assay development, and antibody derivatization. Formerly known as BioProfile Corporation, the name was changed to Singulex, Inc. in 2003.